ImmunityBio's cell therapy posts encouraging early data in rare blood cancer

ImmunityBio’s off-the-shelf cell therapy has shown early promise in a small trial in a rare form of lymphoma. The ongoing Phase 1 study, named QUILT-106, has so far signed up four patients with Waldenström non ...